N-[2-(3,4-Dihydro-1-oxo-2(1H)-isoquinolinyl)-2-oxoethyl]-N-formyl-cyclohexanecarboxamide

N-[2-(3,4-Dihydro-1-oxo-2(1H)-isoquinolinyl)-2-oxoethyl]-N-formyl-cyclohexanecarboxamide, also known as DAA-1106, is a small molecule drug that has been shown to have potential therapeutic effects in the treatment of various neurological disorders. It belongs to the class of compounds known as quinolinecarboxamides, which are known to have anti-inflammatory and neuroprotective properties. DAA-1106 acts as an agonist of the sigma-1 receptor, a protein that is highly expressed in the central nervous system and is involved in various cellular processes such as ion channel regulation, neurotransmitter release, and calcium signaling. Activation of the sigma-1 receptor has been shown to have neuroprotective effects, making it a potential target for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. In addition to its neuroprotective effects, DAA-1106 has also been shown to have anti-inflammatory properties, which may contribute to its therapeutic potential in the treatment of various inflammatory conditions such as multiple sclerosis and rheumatoid arthritis. Chemically, DAA-1106 has a molecular weight of 429.5 g/mol and a molecular formula of C24H28N2O4. It is a white to off-white crystalline powder that is soluble in organic solvents such as DMSO and ethanol. DAA-1106 has undergone extensive preclinical testing and has shown promising results in animal models of neurological disorders, making it a potential candidate for further clinical development.